Immune cell death-related lncRNA signature as a predictive factor of clinical outcomes and immune checkpoints in gastric cancer

Frontiers in Pharmacology

Pharmacology

Zeyu Zhang¹  Duntao Su¹  Fada Xia¹  Yuanliang Yan²  Abhimanyu Thakur³  Kui Zhang⁴ 

[1] Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China;Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China;National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China;Pritzker School of Molecular Engineering, Ben May Department for Cancer Research, University of Chicago, Chicago, IL, United States;State Key Laboratory of Silkworm Genome Biology, Medical Research Institute, Southwest University, Chongqing, China;

关键词: gastric cancer;    immune cell death;    lncRNAs;    prognostic signature;    tumor immune microenvironment;   

DOI  :  10.3389/fphar.2023.1162995

 received in 2023-02-10, accepted in 2023-03-20,  发布年份 2023

来源: Frontiers

【 摘 要 】

Background: Immune cell death (ICD) is a type of tumor cell death that has recently been shown to activate and regulate tumor immunity. However, the role of ICD-related long non-coding RNAs (lncRNAs) in gastric cancer remains to be clarified.Methods: We obtained 375 tumor samples from the Cancer Genome Atlas (TCGA) database and randomly assigned them to training and verification groups. LASSO and Cox regression analysis were utilized to identify ICD-related lncRNAs and establish a risk model. The changes in the immune microenvironment of the two groups were compared by examining the tumor-infiltrating immune cells.Results: We established a tumor signature based on nine ICD-related lncRNAs. In light of the receiver operating characteristic and Kaplan–Meier curves, the prognostic values of this risk model were verified. Multivariate regression analysis showed that the risk score was an independent risk factor for the prognosis of patients in both the training cohort (HR 2.52; 95% CI: 1.65–3.87) and validation cohort (HR 2.70; 95% CI: 1.54–4.8). A nomogram was developed to predict the 1-, 3-, and 5-year survival of patients with gastric cancer, and the signature was linked to high levels of immunological checkpoint expression (B7-H3, VSIR).Conclusions: An ICD-related lncRNA signature could predict the immune response and prognosis of patients with gastric cancer. This prognostic signature could be employed to independently monitor the efficacy of immunotherapy for gastric cancer patients.

【 授权许可】

Unknown   
Copyright © 2023 Zhang, Su, Thakur, Zhang, Xia and Yan.